Roles of inflammation, oxidative stress, and vascular dysfunction in hypertension

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Dinh, Quynh N ^a   Drummond, Grant R ^a   Sobey, Christopher G ^a   Chrissobolis, Sophocles ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ANTIHYPERTENSIVE AGENT; ANTIINFLAMMATORY AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADRENERGIC SYSTEM; AGING; ANTIHYPERTENSIVE THERAPY; CHRONIC INFLAMMATION; CLINICAL TRIAL (TOPIC); ENDOTHELIAL DYSFUNCTION; EXPERIMENTAL HYPERTENSION; HUMAN; HYPERTENSION; INFLAMMATION; NONHUMAN; OXIDATIVE STRESS; PHASE 2 CLINICAL TRIAL (TOPIC); REVIEW; UNSPECIFIED SIDE EFFECT; VASCULAR DISEASE; ANIMAL; PATHOLOGY; PATHOPHYSIOLOGY; VASCULAR ENDOTHELIUM;

ANIMALS; ENDOTHELIUM, VASCULAR; HUMANS; HYPERTENSION; INFLAMMATION; OXIDATIVE STRESS; SYMPATHETIC NERVOUS SYSTEM;

EID: 84928471327     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/406960     Document Type: Review

References (142)

1. H. O. Ventura, S. J. Taler, and J. E. Strobeck, "Hypertension as a hemodynamic disease: the role of impedance cardiography in diagnostic, prognostic, and therapeutic decision making, " The American Journal of Hypertension, vol. 18, no. 2, pp. 26S-43S, 2005.
2. P. M. Kearney, M. Whelton, K. Reynolds, P. Muntner, P. K. Whelton, and J. He, "Global burden of hypertension: Analysis of worldwide data, " The Lancet, vol. 365, no. 9455, pp. 217-223, 2005.
3. F. H. Messerli, B. Williams, and E. Ritz, "Essential hypertension, " The Lancet, vol. 370, no. 9587, pp. 591-603, 2007.
4. E. Onusko, "Diagnosing secondary hypertension, " The American Family Physician, vol. 67, no. 1, pp. 67-74, 2003.
5. F. Turnbull, "Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectivelydesigned overviews of randomised trials, " The Lancet, vol. 362, no. 9395, pp. 1527-1535, 2003.
6. S. Bhanot and J. H. McNeill, "Insulin and hypertension: a causal relationship?" Cardiovascular Research, vol. 31, no. 2, pp. 212-221, 1996.
7. L. T. Tran, V. G. Yuen, and J. H. McNeill, "The fructosefed rat: a review on the mechanisms of fructose-induced insulin resistance and hypertension, " Molecular and Cellular Biochemistry, vol. 332, no. 1-2, pp. 145-159, 2009.
8. R. A. DeFronzo and E. Ferrannini, "Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease, " Diabetes Care, vol. 14, no. 3, pp. 173-194, 1991.
9. M. P. Keane and R. M. Strieter, "Chemokine signaling in inflammation, " Critical Care Medicine, vol. 28, no. 4, pp. N13-N26, 2000.
10. A. J. Lusis, "Atherosclerosis, " Nature, vol. 407, no. 6801, pp. 233-241, 2000.
11. S. E. Sweeney and G. S. Firestein, "Rheumatoid arthritis: regulation of synovial inflammation, " International Journal of Biochemistry and Cell Biology, vol. 36, no. 3, pp. 372-378, 2004.
12. Y. F. Asanuma, "Accelerated atherosclerosis and inflammation in systemic lupus erythematosus, " Japanese Journal of Clinical Immunology, vol. 35, no. 6, pp. 470-480, 2012.
13. R. F. Mortensen and W. Zhong, "Regulation of phagocytic leukocyte activities by C-reactive protein, " Journal of Leukocyte Biology, vol. 67, no. 4, pp. 495-500, 2000.
14. S. P. Ballou and G. Lozanski, "Induction of inflammatory cytokine release from cultured humanmonocytes by C-reactive protein, " Cytokine, vol. 4, no. 5, pp. 361-368, 1992.
15. V. Pasceri, J. T. Willerson, and E. T. H. Yeh, "Direct proinflammatory effect of C-reactive protein on human endothelial cells, " Circulation, vol. 102, no. 18, pp. 2165-2168, 2000.
16. C. Stumpf, J. Jukic, A. Yilmaz et al., "Elevated VEGF-plasma levels in young patients with mild essential hypertension, " European Journal of Clinical Investigation, vol. 39, no. 1, pp. 31-36, 2009.
17. L. E. Bautista, J. E. Atwood, P. G. OMalley, and A. J. Taylor, "Association between C-reactive protein and hypertension in healthy middle-aged men and women, " Coronary Artery Disease, vol. 15, no. 6, pp. 331-336, 2004.
18. G. J. Blake, N. Rifai, J. E. Buring, and P. M. Ridker, "Blood pressure, C-reactive protein, and risk of future cardiovascular events, " Circulation, vol. 108, no. 24, pp. 2993-2999, 2003.
19. E. M. Stuveling, S. J. L. Bakker, H. L. Hillege et al., "C-reactive protein modifies the relationship between blood pressure and microalbuminuria, " Hypertension, vol. 43, no. 4, pp. 791-796, 2004.
20. K. C. Sung, J. Y. Suh, B. S. Kim et al., "High sensitivity Creactive protein as an independent risk factor for essential hypertension, " American Journal of Hypertension, vol. 16, no. 6, pp. 429-433, 2003.
21. T. Xu, Z. Ju, W. Tong et al., "Relationship of C-reactive protein with hypertension and interactions between increased C-reactive protein and other risk factors on hypertension in Mongolian people, China, " Circulation Journal, vol. 72, no. 8, pp. 1324-1328, 2008.
22. C. Chrysohoou, C. Pitsavos, D. B. Panagiotakos, J. Skoumas, and C. Stefanadis, "Association between prehypertension status and inflammatory markers related to atherosclerotic disease: the ATTICA Study, "The American Journal of Hypertension, vol. 17, no. 7, pp. 568-573, 2004.
23. H. D. Sesso, J. E. Buring, N. Rifai, G. J. Blake, J. M. Gaziano, and P. M. Ridker, "C-reactive protein and the risk of developing hypertension, " Journal of the AmericanMedical Association, vol. 290, no. 22, pp. 2945-2951, 2003.
24. V. Dauphinot, F. Roche, M. P. Kossovsky et al., "C-reactive protein implications in new-onset hypertension in a healthy population initially aged 65 years: the Proof study, " Journal of Hypertension, vol. 27, no. 4, pp. 736-743, 2009.
25. L. Niskanen, D. E. Laaksonen, K. Nyyssonen et al., "Inflammation, abdominal obesity, and smoking as predictors of hypertension, " Hypertension, vol. 44, no. 6, pp. 859-865, 2004.
26. R. Tkacova, "Systemic inflammation in chronic obstructive pulmonary disease: may adipose tissue play a role? Review of the literature and future perspectives, " Mediators of Inflammation, vol. 2010, Article ID 585989, 2010.
27. W. Lieb, M. J. Pencina, T. J. Wang et al., "Association of parental hypertension with concentrations of select biomarkers in nonhypertensive offspring, " Hypertension, vol. 52, no. 2, pp. 381-386, 2008.
28. L. E. Bautista, L. M. Vera, I. A. Arenas, and G. Gamarra, "Independent association between inflammatory markers (Creactive protein, interleukin-6, and TNF-alpha) and essential hypertension, " Journal of HumanHypertension, vol. 19, no. 2, pp. 149-154, 2005.
29. C. U. Chae, R. T. Lee, N. Rifai, and P. M. Ridker, "Blood pressure and inflammation in apparently healthy men, " Hypertension, vol. 38, no. 3, pp. 399-403, 2001.
30. J.-M. Fernandez-Real, M. Vayreda, C. Richart et al., "Circulating interleukin 6 levels, blood pressure, and insulin sensitivity in apparently healthy men and women, " The Journal of Clinical Endocrinology and Metabolism, vol. 86, no. 3, pp. 1154-1159, 2001.
31. S. Zhao, Q. Li, L. Liu, Z. Xu, and J. Xiao, "Simvastatin reduces interleukin-1beta secretion by peripheral blood mononuclear cells in patients with essential hypertension, " Clinica Chimica Acta, vol. 344, no. 1-2, pp. 195-200, 2004.
32. G. N. Dalekos, M. Elisaf, E. Bairaktari, O. Tsolas, and K. C. Siamopoulos, "Increased serum levels of interleukin-1β in the systemic circulation of patients with essential hypertension: additional risk factor for atherogenesis in hypertensive patients?" Journal of Laboratory and Clinical Medicine, vol. 129, no. 3, pp. 300-308, 1997.
33. X. Yu, Z. Yang, and M. Yu, "Correlation of tumor necrosis factor alpha and interleukin 6 with hypertensive renal damage, " Renal Failure, vol. 32, no. 4, pp. 475-479, 2010.
34. T. Furumoto, N. Saito, J. Dong, T. Mikami, S. Fujii, and A. Kitabatake, "Association of cardiovascular risk factors and endothelial dysfunction in Japanese hypertensive patients: implications for early atherosclerosis, " Hypertension Research, vol. 25, no. 3, pp. 475-480, 2002.
35. J. Youn, H. T. Yu, B. J. Lim et al., "Immunosenescent CD8+ T clls and C-X-C cemokine receptor type 3 chemokines are increased in human hypertension, " Hypertension, vol. 62, no. 1, pp. 126-133, 2013.
36. E. C. Seaberg, A. Munoz, M. Lu et al., "Association between highly active antiretroviral therapy and hypertension in a large cohort of men followed from 1984 to 2003, " AIDS, vol. 19, no. 9, pp. 953-960, 2005.
37. N. A. Hodyl, M. J. Stark, A. Osei-Kumah, and V. L. Clifton, "Prenatal programming of the innate immune response following in utero exposure to inflammation: a sexually dimorphic process?" Expert Review of Clinical Immunology, vol. 7, no. 5, pp. 579-592, 2011.
38. M. E. Msall, G. M. Buck, B. T. Rogers et al., "Multivariate risks among extremely premature infants, " Journal of Perinatology, vol. 14, no. 1, pp. 41-47, 1994.
39. F. Mwanyumba, I. Inion, P. Gaillard, K. Mandaliya, M. Praet, and M. Temmerman, "Placental inflammation and perinatal outcome, " European Journal ofObstetrics Gynecology and Reproductive Biology, vol. 108, no. 2, pp. 164-170, 2003.
40. B. Rodriguez-Iturbe, Y. Quiroz, A. Ferrebuz, G. Parra, and N. D. Vaziri, "Evolution of renal interstitial inflammation and NF-κB activation in spontaneously hypertensive rats, " American Journal of Nephrology, vol. 24, no. 6, pp. 587-594, 2004.
41. H. Waki, B. Liu, M. Miyake et al., "Junctional adhesion molecule-1 is upregulated in spontaneously hypertensive rats: evidence for a prohypertensive role within the brain stem, " Hypertension, vol. 49, no. 6, pp. 1321-1327, 2007.
42. C. De Ciuceis, F. Amiri, P. Brassard, D. H. Endemann, R. M. Touyz, and E. L. Schiffrin, "Reduced vascular remodeling, endothelial dysfunction, and oxidative stress in resistance arteries of angiotensin II-infused macrophage colony-stimulating factor-deficient mice: evidence for a role in inflammation in angiotensin-induced vascular injury, " Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 25, no. 10, pp. 2106-2113, 2005.
43. W. Zhang, W. Wang, H. Yu et al., "Interleukin 6 underlies angiotensin II-induced hypertension and chronic renal damage, " Hypertension, vol. 59, no. 1, pp. 136-144, 2012.
44. S. Sriramula, M. Haque, D. S. A. Majid, and J. Francis, "Involvement of tumor necrosis factor-α in angiotensin II-mediated effects on salt appetite, hypertension, and cardiac hypertrophy, " Hypertension, vol. 51, no. 5, pp. 1345-1351, 2008.
45. M. S. Madhur, H. E. Lob, L. A. McCann et al., "Interleukin 17 promotes angiotensin II-induced hypertension and vascular dysfunction, " Hypertension, vol. 55, no. 2, pp. 500-507, 2010.
46. P. Crosswhite and Z. Sun, "Ribonucleic acid interference knockdown of interleukin 6 attenuates cold-induced hypertension, " Hypertension, vol. 55, no. 6, pp. 1484-1491, 2010.
47. B. Rodriguez-Iturbe, A. Ferrebuz, V. Vanegas, Y. Quiroz, S. Mezzano, and N. D. Vaziri, "Early and sustained inhibition of nuclear factor-κB prevents hypertension in spontaneously hypertensive rats, " Journal of Pharmacology and Experimental Therapeutics, vol. 315, no. 1, pp. 51-57, 2005.
48. K. L. H. Wu, S. H. H. Chan, and J. Y. H. Chan, "Neuroinflammation and oxidative stress in rostral ventrolateralmedulla contribute to neurogenic hypertension induced by systemic inflammation, " Journal of Neuroinflammation, vol. 9, no. 1, article 212, 2012.
49. Y. L. Wei, X. H. Li, and J. Z. Zhou, "Prenatal exposure to lipopolysaccharide results in increases in blood pressure and body weight in rats, " Acta Pharmacologica Sinica, vol. 28, no. 5, pp. 651-656, 2007.
50. X.-Q. Hao, H.-G. Zhang, Z.-B. Yuan, D. Yang, L. Hao, and X. Li, "Prenatal exposure to lipopolysaccharide alters the intrarenal renin-angiotensin system and renal damage in offspring rats, " Hypertension Research, vol. 33, no. 1, pp. 76-82, 2010.
51. A. Samuelsson, I. Ohrn, J. Dahlgren et al., "Prenatal exposure to interleukin-6 results in hypertension and increased hypothalamic-pituitary-adrenal axis activity in adult rats, " Endocrinology, vol. 145, no. 11, pp. 4897-4911, 2004.
52. T. J. Guzik, N. E. Hoch, K. A. Brown et al., "Role of the T cell in the genesis of angiotensin II-induced hypertension and vascular dysfunction, " Journal of ExperimentalMedicine, vol. 204, no. 10, pp. 2449-2460, 2007.
53. P. J. Marvar, A. Vinh, S. Thabet et al., "T lymphocytes and vascular inflammation contribute to stress-dependent hypertension, " Biological Psychiatry, vol. 71, no. 9, pp. 774-782, 2012.
54. P. Wenzel, M. Knorr, S. Kossmann et al., "LysozymeM-positive monocytes mediate angiotensin ii-induced arterial hypertension and vascular dysfunction, " Circulation, vol. 124, no. 12, pp. 1370-1381, 2011.
55. M. Jurewicz, D. H. McDermott, J. M. Sechler et al., "Human T and natural killer cells possess a functional renin-angiotensin system: further mechanisms of angiotensin II-induced inflammation, " Journal of the American Society of Nephrology, vol. 18, no. 4, pp. 1093-1102, 2007.
56. N. E. Hoch, T. J. Guzik, W. Chen et al., "Regulation of T-cell function by endogenously produced angiotensin II, " American Journal of Physiology. Regulatory, Integrative and Comparative Physiology, vol. 296, no. 2, pp. R208-R216, 2009.
57. S. Kim and H. Iwao, "Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases, " Pharmacological Reviews, vol. 52, no. 1, pp. 11-34, 2000.
58. C. Wang, S. Li, R. D. Weisel et al., "C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle, " Circulation, vol. 107, no. 13, pp. 1783-1790, 2003.
59. D. Gurantz, R. T. Cowling, N. Varki, E. Frikovsky, C. D. Moore, and B. H. Greenberg, "IL-1β and TNF-α upregulate angiotensin II type 1 (AT 1) receptors on cardiac fibroblasts and are associated with increased AT1 density in the post-MI heart, " Journal of Molecular and Cellular Cardiology, vol. 38, no. 3, pp. 505-515, 2005.
60. Z. H. Zhang, Y. Yu, S. Wei, and R. B. Felder, "Centrally administered lipopolysaccharide elicits sympathetic excitation via NAD(P)H oxidase-dependent mitogen-activated protein kinase signaling, " Journal of Hypertension, vol. 28, no. 4, pp. 806-816, 2010.
61. D. W. Trott and D. G. Harrison, "The immune system in hypertension, " Advances in Physiology Education, vol. 38, no. 1, pp. 20-24, 2014.
62. D. G. Harrison, T. J. Guzik, H. E. Lob et al., "Inflammation, immunity, and hypertension, " Hypertension, vol. 57, no. 2, pp. 132-140, 2011.
63. S. Chrissobolis, A. A. Miller, G. R. Drummond, B. K. Kemp-Harper, and C. G. Sobey, "Oxidative stress and endothelial dysfunction in cerebrovascular disease, " Frontiers in Bioscience, vol. 16, no. 5, pp. 1733-1745, 2011.
64. S. Chrissobolis and F. M. Faraci, "The role of oxidative stress and NADPH oxidase in cerebrovascular disease, " Trends in Molecular Medicine, vol. 14, no. 11, pp. 495-502, 2008.
65. C. Baylis, B. Mitruka, and A. Deng, "Chronic blockade of nitric oxide synthesis in the rat produces systemic hypertension and glomerular damage, " Journal ofClinical Investigation, vol. 90, no. 1, pp. 278-281, 1992.
66. S. Verma, C. Wang, S. Li et al., "A self-fulfilling prophecy: Creactive protein attenuates nitric oxide production and inhibits angiogenesis, " Circulation, vol. 106, no. 8, pp. 913-919, 2002.
67. G. Yan, B. You, S. Chen, J. K. Liao, and J. Sun, "Tumor necrosis factor-α downregulates endothelial nitric oxide synthase mRNA stability via translation elongation factor 1-α 1, " Circulation Research, vol. 103, no. 6, pp. 591-597, 2008.
68. K. M. Maki-Petaja, F. C. Hall, A. D. Booth et al., "Rheumatoid arthritis is associated with increased aortic pulse-wave velocity, which is reduced by anti-tumor necrosis factor-α therapy, " Circulation, vol. 114, no. 11, pp. 1185-1192, 2006.
69. H. Nguyen, V. L. Chiasson, P. Chatterjee, S. E. Kopriva, K. J. Young, and B. M. Mitchell, "Interleukin-17 causes Rhokinase-mediated endothelial dysfunction and hypertension, " Cardiovascular Research, vol. 97, no. 4, pp. 696-704, 2013.
70. I. Fleming, J. Bauersachs, A. Schafer, D. Scholz, J. Aldershvile, and R. Busse, "Isometric contraction induces the Ca2+-independent activation of the endothelial nitric oxidesynthase, " Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 3, pp. 1123-1128, 1999.
71. S. Chrissobolis and C. G. Sobey, "Evidence that Rho-kinase activity contributes to cerebral vascular tone in vivo and is enhanced during chronic hypertension: comparison with protein kinase C, " Circulation Research, vol. 88, no. 8, pp. 774-779, 2001.
72. S. Fichtlscherer, S. Breuer, V. Schachinger, S. Dimmeler, and A. M. Zeiher, "C-reactive protein levels determine systemic nitric oxide bioavailability in patients with coronary artery disease, " European Heart Journal, vol. 25, no. 16, pp. 1412-1418, 2004.
73. P. Kubes, M. Suzuki, and D. N. Granger, "Nitric oxide: an endogenous modulator of leukocyte adhesion, " Proceedings of the National Academy of Sciences of the United States of America, vol. 88, no. 11, pp. 4651-4655, 1991.
74. A. M. Zeiher, B. Fisslthaler, B. Schray-Utz, and R. Busse, "Nitric oxide modulates the expression of monocyte chemoattractant protein 1 in cultured human endothelial cells, " Circulation Research, vol. 76, no. 6, pp. 980-986, 1995.
75. H. Tomita, K. Egashira, M. Kubo-Inoue et al., "Inhibition of NO synthesis induces inflammatory changes and monocyte chemoattractant protein-1 expression in rat hearts and vessels, " Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 18, no. 9, pp. 1456-1464, 1998.
76. H. Qian, V. Neplioueva, G. A. Shetty, K. M. Channon, and S. E. George, "Nitric oxide synthase gene therapy rapidly reduces adhesion molecule expression and inflammatory cell infiltration in carotid arteries of cholesterol-fed rabbits, " Circulation, vol. 99, no. 23, pp. 2979-2982, 1999.
77. S. D. Crowley, "The cooperative roles of inflammation and oxidative stress in the pathogenesis of hypertension, " Antioxidants and Redox Signaling, vol. 20, no. 1, pp. 102-120, 2014.
78. G. R. Drummond, S. Selemidis, K. K. Griendling, and C. G. Sobey, "Combating oxidative stress in vascular disease:NADPH oxidases as therapeutic targets, " Nature Reviews Drug Discovery, vol. 10, no. 6, pp. 453-471, 2011.
79. R. M. Touyz, "Reactive oxygen species and angiotensin II signaling in vascular cells-implications in cardiovascular disease, " Brazilian Journal of Medical and Biological Research, vol. 37, no. 8, pp. 1263-1273, 2004.
80. R. E. Huie and S. Padmaja, "Thereaction of no with superoxide, " Free Radical Research Communications, vol. 18, no. 4, pp. 195-199, 1993.
81. A. Cudd and I. Fridovich, "Electrostatic interactions in the reaction mechanism of bovine erythrocyte superoxide dismutase, " Journal of Biological Chemistry, vol. 257, no. 19, pp. 11443-11447, 1982.
82. J. Vasquez-Vivar, B. Kalyanaraman, P. Martasek et al., "Superoxide generation by endothelial nitric oxide synthase: the influence of cofactors, " Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 16, pp. 9220-9225, 1998.
83. E. A. Hassoun, F. Li, A. Abushaban, and S. J. Stohs, "Production of superoxide anion, lipid peroxidation and DNA damage in the hepatic and brain tissues of rats after subchronic exposure to mixtures of TCDD and its congeners, " Journal of Applied Toxicology, vol. 21, no. 3, pp. 211-219, 2001.
84. T. G. Canty Jr., E. M. Boyle Jr., A. Farr, E. N. Morgan, E. D. Verrier, and T. H. Pohlman, "Oxidative stress induces NF-κB nuclear translocation without degradation of IκBα. Circulation, " Circulation, vol. 100, no. 19, pp. II-361-II-364, 1999.
85. K. Yasunari, K. Maeda, M. Nakamura, and J. Yoshikawa, "Oxidative stress in leukocytes is a possible link between blood pressure, blood glucose, and C-reacting protein, " Hypertension, vol. 39, no. 3, pp. 777-780, 2002.
86. R. N. Foley and A. J. Collins, "End-stage renal disease in the United States: an update from the United States Renal Data System, " Journal of the American Society of Nephrology, vol. 18, no. 10, pp. 2644-2648, 2007.
87. E. Dounousi, E. Papavasiliou, A. Makedou et al., "Oxidative stress is progressively enhanced with advancing stages of CKD, " American Journal of Kidney Diseases, vol. 48, no. 5, pp. 752-760, 2006.
88. E. M. Stuveling, H. L. Hillege, S. J. L. Bakker, R. O. B. Gans, P. E. De Jong, and D. De Zeeuw, "C-reactive protein is associated with renal function abnormalities in a non-diabetic population, " Kidney International, vol. 63, no. 2, pp. 654-661, 2003.
89. S. K. Biswas and J. B. L. de Faria, "Which comes first: renal inflammation or oxidative stress in spontaneously hypertensive rats?" Free Radical Research, vol. 41, no. 2, pp. 216-224, 2007.
90. D. Lao, P. S. Parasher, K. C. Cho, and Y. Yeghiazarians, "Atherosclerotic renal artery stenosis-diagnosis and treatment, " Mayo Clinic Proceedings, vol. 86, no. 7, pp. 649-657, 2011.
91. M. R. Khatami, "Ischemic nephropathy: more than a simple renal artery narrowing, " Iranian Journal of Kidney Diseases, vol. 7, no. 2, pp. 82-100, 2013.
92. K. J. Hansen, M. S. Edwards, T. E. Craven et al., "Prevalence of renovascular disease in the elderly: a population-based study, " Journal of Vascular Surgery, vol. 36, no. 3, pp. 443-451, 2002.
93. C. Weber and H. Noels, "Atherosclerosis: current pathogenesis and therapeutic options, " Nature Medicine, vol. 17, no. 11, pp. 1410-1422, 2011.
94. P. G. Guyenet, "The sympathetic control of blood pressure, " Nature Reviews Neuroscience, vol. 7, no. 5, pp. 335-346, 2006.
95. M. P. Schlaich, E. Lambert, D. M. Kaye et al., "Sympathetic augmentation in hypertension: role of nerve firing, norepinephrine reuptake, and angiotensin neuromodulation, " Hypertension, vol. 43, no. 2 I, pp. 169-175, 2004.
96. Z.-Y. Tan, Y. Lu, C. A. Whiteis et al., "Chemoreceptor hypersensitivity, sympathetic excitation, and overexpression of ASIC and TASK channels before the onset of hypertension in SHR, " Circulation Research, vol. 106, no. 3, pp. 536-545, 2010.
97. D. M. Nance and V. M. Sanders, "Autonomic innervation and regulation of the immune system(1987-2007), " Brain, Behavior, and Immunity, vol. 21, no. 6, pp. 736-745, 2007.
98. H. E. Lob, P. J. Marvar, T. J. Guzik et al., "Induction of hypertension and peripheral inflammation by reduction of extracellular superoxide dismutase in the central nervous system, " Hypertension, vol. 55, no. 2, pp. 277-283, 2010.
99. R. Veelken, E. Vogel, K. Hilgers et al., "Autonomic renal denervation ameliorates experimental glomerulonephritis, " Journal of the American Society of Nephrology, vol. 19, no. 7, pp. 1371-1378, 2008.
100. Y. Yu, Z. Zhang, S. Wei, J. Serrats, R. M. Weiss, and R. B. Felder, "Brain perivascular macrophages and the sympathetic response to inflammation in rats after myocardial infarction, " Hypertension, vol. 55, no. 3, pp. 652-659, 2010.
101. R. D. Bunag, I. H. Page, and J. W. McCubbin, "Neural stimulation of release of renin, " Circulation Research, vol. 19, no. 4, pp. 851-858, 1966.
102. M. D. Esler, H. Krum, M. Schlaich, R. E. Schmieder, M. Bohm, and P. A. Sobotka, "Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the symplicity htn-2 randomized, controlled trial, " Circulation, vol. 126, no. 25, pp. 2976-2982, 2012.
103. D. L. Bhatt, D. E. Kandzari, W. W. ONeill et al., "A controlled trial of renal denervation for resistant hypertension, " The New England Journal ofMedicine, vol. 370, no. 15, pp. 1393-1401, 2014.
104. H. Krum, "Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months, " Hypertension, vol. 57, no. 5, pp. 911-917, 2011.
105. S. Verheye, "TCT-62 preliminary result of the rapid renal sympathetic denervation for resistant hypertension using the maya medical OneShot(tm) Ablation System (RAPID) study, " Journal of the American College of Cardiology, vol. 62, no. 18, supplement 1, p. B20, 2013.
106. P. Lloyd-Sherlock, J. Beard, N. Minicuci, S. Ebrahim, and S. Chatterji, "Hypertension among older adults in low-and middle-income countries: prevalence, awareness and control, " International Journal of Epidemiology, vol. 43, no. 1, pp. 116-128, 2014.
107. C. T. M. van Rossum, H. van de Mheen, J. C. M. Witteman, A. Hofman, J. P. Mackenbach, and D. E. Grobbee, "Prevalence, treatment, and control of hypertension by sociodemographic factors among the Dutch elderly, " Hypertension, vol. 35, no. 3, pp. 814-821, 2000.
108. M. A. Rafey, "Resistant hypertension in the elderly, " Clinics in Geriatric Medicine, vol. 25, no. 2, pp. 289-301, 2009.
109. C. Franceschi, M. Capri, D. Monti et al., "Inflammaging and anti-inflammaging: a systemic perspective on aging and longevity emerged from studies in humans, " Mechanisms of Ageing and Development, vol. 128, no. 1, pp. 92-105, 2007.
110. D. B. Bartlett, C. M. Firth, A. C. Phillips et al., "The age-related increase in low-grade systemic inflammation (Inflammaging) is not driven by cytomegalovirus infection, " Aging Cell, vol. 11, no. 5, pp. 912-915, 2012.
111. J. W. Funder, R. M. Carey, C. Fardella et al., "Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline, " Journal of Clinical Endocrinology and Metabolism, vol. 93, no. 9, pp. 3266-3281, 2008.
112. A. Struthers, H. Krum, and G. H. Williams, "A comparison of the aldosterone-blocking agents eplerenone and spironolactone, " Clinical Cardiology, vol. 31, no. 4, pp. 153-158, 2008.
113. F. C. Luft, "Mendelian forms of human hypertension and mechanisms of disease., " Clinical Medicine and Research, vol. 1, no. 4, pp. 291-300, 2003.
114. Z. Zhang, Y. Yu, Y. Kang, S. Wei, and R. B. Felder, "Aldosterone acts centrally to increase brain renin-angiotensin system activity and oxidative stress in normal rats, " The American Journal of Physiology: Heart and Circulatory Physiology, vol. 294, no. 2, pp. H1067-H1074, 2008.
115. E. Leibovitz, T. Ebrahimian, P. Paradis, and E. L. Schiffrin, "Aldosterone induces arterial stiffness in absence of oxidative stress and endothelial dysfunction, " Journal of Hypertension, vol. 27, no. 11, pp. 2192-2200, 2009.
116. R. Rocha, A. E. Rudolph, G. E. Frierdich et al., "Aldosterone induces a vascular inflammatory phenotype in the rat heart, " American Journal of Physiology: Heart and Circulatory Physiology, vol. 283, no. 5, pp. H1802-H1810, 2002.
117. Y. Sun, J. Zhang, L. Lu, S. S. Chen, M. T. Quinn, and K. T. Weber, "Aldosterone-induced inflammation in the rat heart: role of oxidative stress, " The American Journal of Pathology, vol. 161, no. 5, pp. 1773-1781, 2002.
118. D. A. Kasal, T. Barhoumi, M. W. Li et al., "T regulatory lymphocytes prevent aldosterone-induced vascular injury, " Hypertension, vol. 59, no. 2, pp. 324-330, 2012.
119. E. R. Blasi, R. Rocha, A. E. Rudolph, E. A. G. Blomme, M. L. Polly, and E. G. McMahon, "Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats, " Kidney International, vol. 63, no. 5, pp. 1791-1800, 2003.
120. V. Tzamou, G. Vyssoulis, E. Karpanou, S.-. Kyvelou, T. Gialernios, and C. Stefanadis, "Aldosterone levels and inflammatory stimulation in essential hypertensive patients, " Journal of Human Hypertension, vol. 27, no. 9, pp. 535-538, 2013.
121. B. Rodriguez-Iturbe, Y. Quiroz, M. Nava et al., "Reduction of renal immune cell infiltration results in blood pressure control in genetically hypertensive rats, " The American Journal of Physiology: Renal Physiology, vol. 282, no. 2, pp. F191-F201, 2002.
122. N. Tian, J.-W. Gu, S. Jordan, R. A. Rose, M. D. Hughson, and R. D. Manning Jr., "Immune suppression prevents renal damage and dysfunction and reduces arterial pressure in salt-sensitive hypertension, " The American Journal of Physiology-Heart and Circulatory Physiology, vol. 292, no. 2, pp. H1018-H1025, 2007.
123. D. L. Mattson, L. James, E. A. Berdan, and C. J. Meister, "Immune suppression attenuates hypertension and renal disease in the Dahl salt-sensitive rat, " Hypertension, vol. 48, no. 1, pp. 149-156, 2006.
124. J. Herrera, A. Ferrebuz, E. G. MacGregor, and B. Rodriguez-Iturbe, "Mycophenolate mofetil treatment improves hypertension in patients with psoriasis and rheumatoid arthritis, " Journal of the American Society of Nephrology, vol. 17, supplement 3, no. 12, pp. S218-S225, 2006.
125. C. de Miguel, C. Guo, H. Lund, D. Feng, and D. L. Mattson, "Infiltrating T lymphocytes in the kidney increase oxidative stress and participate in the development of hypertension and renal disease, " The American Journal of Physiology-Renal Physiology, vol. 300, no. 3, pp. F734-F742, 2011.
126. C. J. Ferro, N. C. Edwards, C. Hutchison et al., "Does immunosuppressant medication lower blood pressure and arterial stiffness in patients with chronic kidney disease? An observational study, " Hypertension Research, vol. 34, no. 1, pp. 113-119, 2011.
127. C. Nataraj, M. I. Oliverio, R. B. Mannon et al., "Angiotensin II regulates cellular immune responses through a calcineurindependent pathway, " Journal of Clinical Investigation, vol. 104, no. 12, pp. 1693-1701, 1999.
128. A. C. Tissot, P. Maurer, J. Nussberger et al., "Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebocontrolled phase IIa study, " The Lancet, vol. 371, no. 9615, pp. 821-827, 2008.
129. X. Chen, Z. Qiu, S. Yang et al., "Effectiveness and safety of a therapeutic vaccine against angiotensin II receptor type 1 in hypertensive animals, " Hypertension, vol. 61, no. 2, pp. 408-416, 2013.
130. J.-B. Michel, C. Guettier, M. Philippe, F. X. Galen, P. Corvol, and J. Menard, "Active immunization against renin in normotensive marmoset, " Proceedings of the National Academy of Sciences of the United States of America, vol. 84, no. 12, pp. 4346-4350, 1987.
131. E. Tepperman, D. Ramzy, J. Prodaer et al., "Surgical biology forthe clinician: vascular effects of immunosuppression, " Canadian Journal of Surgery, vol. 53, no. 1, pp. 57-63, 2010.
132. A. G. Johnson, T. V. Nguyen, and R. O. Day, "Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis, " Annals of Internal Medicine, vol. 121, no. 4, pp. 289-300, 1994.
133. A. Myat, S. R. Redwood, A. C. Qureshi, J. A. Spertus Director, and B. Williams, "Resistant hypertension, " BMJ, vol. 345, no. 7884, Article ID e7473, 2012.
134. E. Pimenta and D. A. Calhoun, "Resistant hypertension: incidence, prevalence, and prognosis, " Circulation, vol. 125, no. 13, pp. 1594-1596, 2012.
135. P. Strazzullo, S. M. Kerry, A. Barbato, M. Versiero, L. DElia, and F. P. Cappuccio, "Do statins reduce blood pressure? A metaanalysis of randomized, controlled trials, " Hypertension, vol. 49, no. 4, pp. 792-798, 2007.
136. S. Kinlay, G. G. Schwartz, A. G. Olsson et al., "High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in theMIRACL study, " Circulation, vol. 108, no. 13, pp. 1560-1566, 2003.
137. P. M. Ridker, E. Danielson, F. A. H. Fonseca et al., "Rosuvastatin to prevent vascular events in men and women with elevated Creactive protein, "The New England Journal ofMedicine, vol. 359, no. 21, pp. 2195-2207, 2008.
138. J. A. Tobert, "Lovastatin and beyond: the history of the HMGCoA reductase inhibitors, " Nature Reviews Drug Discovery, vol. 2, no. 7, pp. 517-526, 2003.
139. A. Iwata, R. Shirai, H. Ishii et al., "Inhibitory effect of statins on inflammatory cytokine production from human bronchial epithelial cells, " Clinical and Experimental Immunology, vol. 168, no. 2, pp. 234-240, 2012.
140. U. Laufs and J. K. Liao, "Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase, " Journal of Biological Chemistry, vol. 273, no. 37, pp. 24266-24271, 1998.
141. T.-M. Lu, Y.-A. Ding, H.-B. Leu, W.-H. Yin, W. H.-H. Sheu, and K.-M. Chu, "Effect of rosuvastatin on plasma levels of asymmetric dimethylarginine in patients with hypercholesterolemia, " The American Journal of Cardiology, vol. 94, no. 2, pp. 157-161, 2004.
142. C. Antoniades, C. Shirodaria, P. Leeson et al., "Association of plasma asymmetrical dimethylarginine (ADMA) with elevated vascular superoxide production and endothelial nitric oxide synthase uncoupling: implications for endothelial function in human atherosclerosis, " European Heart Journal, vol. 30, no. 9, pp. 1142-1150, 2009.